TEXT-S&P rates Par Pharmaceutical ‘B+’

Overview — U.S. generic drug manufacturer and marketer Par Pharmaceutical is being purchased by TPG for $2.2 billion, financed with $1.545 billion of debt. — Pro forma for the new debt, we expect a debt-to-EBITDA ratio of 5.3x. — We are …

Share